Protagonist Therapeutics Achieves Milestone In Janssen Collaboration, Triggering $5M Payment

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced the achievement of a research milestone under its worldwide license and research collaboration agreement with Janssen Biotech, Inc. ("Janssen"), for

Benzinga · 01/07/2020 12:10

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced the achievement of a research milestone under its worldwide license and research collaboration agreement with Janssen Biotech, Inc. ("Janssen"), for co-development activities with affiliate Janssen Research & Development, LLC, and commercialization of oral, gut-restricted IL-23 receptor antagonist PTG-200 (JNJ-67864238) and second generation peptides for all indications including inflammatory bowel disease (IBD). The successful nomination of a second-generation development candidate triggers a $5 million milestone payment to Protagonist.